XML 30 R15.htm IDEA: XBRL DOCUMENT
v3.25.1

INTANGIBLE ASSETS | 3 Months Ended
--- | ---
Mar. 31, 2025
Intangible Assets Disclosure [Abstract] |
INTANGIBLE ASSETS | INTANGIBLE ASSETS The following table summarizes our Intangible assets, net:
|  | March 31, 2025 |  | December 31, 2024
(in millions) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset – sofosbuvir |  | $ | 10,720 |  |  | $ | (7,923) |  |  | $ | — |  |  | $ | 2,797 |  |  | $ | 10,720 |  |  | $ | (7,749) |  |  | $ | — |  |  | $ | 2,971 |
Intangible asset – axicabtagene ciloleucel |  | 7,110 |  |  | (2,822) |  |  | — |  |  | 4,288 |  |  | 7,110 |  |  | (2,721) |  |  | — |  |  | 4,389 |
Intangible asset – Trodelvy |  | 11,730 |  |  | (3,353) |  |  | — |  |  | 8,377 |  |  | 11,730 |  |  | (3,083) |  |  | — |  |  | 8,647 |
Intangible asset – Hepcludex |  | 845 |  |  | (351) |  |  | — |  |  | 494 |  |  | 845 |  |  | (329) |  |  | — |  |  | 516 |
Other |  | 1,479 |  |  | (971) |  |  | 1 |  |  | 510 |  |  | 1,474 |  |  | (940) |  |  | 1 |  |  | 535 |
Total finite-lived assets |  | 31,884 |  |  | (15,421) |  |  | 1 |  |  | 16,465 |  |  | 31,879 |  |  | (14,822) |  |  | 1 |  |  | 17,058 |
Indefinite-lived assets – IPR&D(1) |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |  |  | 2,890 |  |  | — |  |  | — |  |  | 2,890 |
Total intangible assets |  | $ | 34,774 |  |  | $ | (15,421) |  |  | $ | 1 |  |  | $ | 19,355 |  |  | $ | 34,769 |  |  | $ | (14,822) |  |  | $ | 1 |  |  | $ | 19,948 |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of March 31, 2025 was comprised of $1.8 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. Impairment Assessments No indicators of impairment were noted for the three months ended March 31, 2025 and 2024, except as described in “2024 Impairment” below. 2024 Impairment In January 2024, we received data from our Phase 3 EVOKE-01 study of Trodelvy evaluating SG indicating that the study did not meet its primary endpoint of overall survival in previously treated metastatic NSCLC, thus triggering a review for potential impairment of the NSCLC IPR&D intangible asset. Based on our evaluation of the study results and all other data currently available, and in connection with the preparation of the financial statements for the first quarter, we performed an interim impairment test and determined that the revised estimated fair value of the NSCLC IPR&D intangible asset was below its carrying value. As a result, we recognized a partial impairment charge of $2.4 billion in In-process research and development impairments on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2024. To arrive at the revised estimated fair value as of March 31, 2024, we used a probability-weighted income approach that discounts expected future cash flows to present value, which requires the use of Level 3 fair value measurements and inputs, including critical estimated inputs, such as: revenues and operating profits related to the planned utilization of SG in NSCLC, which includes inputs such as addressable patient population, projected market share, treatment duration, and the life of the potential commercialized product; the probability of technical and regulatory success; the time and resources needed to complete the development and approval of SG in NSCLC; an appropriate discount rate based on the estimated weighted-average cost of capital for companies with profiles similar to our profile; and risks related to the viability of and potential alternative treatments in any future target markets. We used a discount rate of 7.00% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours.

X
- Definition Intangible Assets Disclosure + References No definition available. + Details
Name: | gild_IntangibleAssetsDisclosureAbstract
Namespace Prefix: | gild_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration